Effect of baseline glycosylated hemoglobin a1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice

Endocrine Practice

Volumn 19, Issue 3, 2013, Pages 462-470

  Caputo, Salvatore ^a   Andersen, Henning ^b   Kaiser, Marcel ^c   Karnieli, Eddy ^d   Meneghini, Luigi F ^e   Svendsen, Anne Louise ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b NOVO NORDISK A S   (Denmark)

^c Practice for Internal Medicine and Diabetology   (Germany)

^d RAMBAM MEDICAL CENTER   (Israel)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; TREATMENT DURATION;

EID: 84880117552     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12269.OR     Document Type: Article

References (36)

1. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007;57:455-460.
2. Pouwer F, Hermanns N. Insulin therapy and quality of life. A review. Diabetes Metab Res Rev. 2009;25(Suppl 1):S4-S10.
3. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm fo. The initiation and adjustment of therapy: a consensus statement o. The American Diabetes Association an. The European Association fo. The Study of Diabetes. Diabetes Care. 2009;32:193-203.
4. Niswender KD. Basal insulin: beyond glycemia. Postgrad Med. 2011;123:27-37.
5. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiaton. The translating research into action starts project. Diabetes Care. 2010;33:733-735.
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement o. The American Diabetes Association (ADA) an. The European Association fo. The Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
7. Davis TM, Davis Cyllene Uwa Edu Au WA, Bruce DG. Glycaemic levels triggering intensification of therapy in type 2 diabetes i. The community. The Fremantle Diabetes Study. Med J Aust. 2006;184:325-328.
8. Jellinger PS, Davidson JA, Blonde L, et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007;13:260-268.
9. O'Keefe JH, Abuannadi M, Lavie CJ, Bell DS. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011;86:128-138.
10. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
11. CG66: Type 2 Diabetes - full guideline. Royal College of Physicians; 2008.
12. CG87: Type 2 diabetes - newer agents. Royal College of Physicians; 2009.
13. Harris SB, Kapor J, Lank CN, Willan AR, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010;56:e418-e424.
14. Control Group, Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288-2298.
15. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration Diabetologia. 2009;52:1219-1226.
16. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis o. The ACCORD randomised trial. Lancet. 2010;376:419-430.
17. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care. 2006;29:2137-2139.
18. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27:309-317.
19. Giugliano D, Maiorino M, Bellastella G, Chiodini P, Esposito K. Relationship of baseline HbA1c, HbA1c change and HbA1c target of
20. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33:1859-1864.
21. Liebl A, Jones S, Benroubi M, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data fro. The INSTIGATE observational study in five European countries. Curr Med Res Opin. 2011;27: 887-895.
22. Khunti K, Damci T, Meneghini LF, Pan CY, Yale JF, SOLVE Study Group. Study of once-daily levemir (SOLVE): insights int. The timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab. 2012;14:654-661.
23. Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data fro. The INSTIGATE study. Curr Med Res Opin. 2009;25:691-700.
24. Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings fro. The Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab. 2008;10(Suppl 1):8-15.
25. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
26. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
27. Greenfield S, Billimek J, Pellegrini F, et al. Comorbidity affect. The relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med. 2009;151:854-860.
28. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
29. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis o. The ACCORD study. BMJ. 2010;340:b4909.
30. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration o. The risk of severe hypoglycaemia: post hoc epidemiological analysis o. The ACCORD study. BMJ. 2010;340:b5444.
31. Meneghini LF, Orozco-Beltran D, Khunti K, et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab. 2011;96:3337-3353.
32. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain Diabetes Obes Metab. 2007;9:209-217.
33. Keating GM. Insulin detemir: a review of its use i. The management of diabetes mellitus. Drugs. 2012;72:2255-2287.
34. Graber AL, Shintani AK, Wolff K, Brown A, Elasy TA. Glycemic relapse in type 2 diabetes. Endocr Pract 2006;12:145-151.
35. Nichols GA, Kimes TM, Harp JB, Kou TD, Brodovicz KG. Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes. Diabetes Care. 2012;35:495-497.
36. Golden SH, Brown A, Cauley JA, et al. Health disparities in endocrine disorders: biological, clinical, and nonclinical factors-an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2012;97:E1579-E1639.